|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
The most potent vasoconstrictor, endothelin-1 and its receptors, endothelin receptor A (EDNRA) and endothelin receptor B (EDNRB) are involved in hypertension.
|
31150867 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Mφ and ET-1 may play an important role in BP control and potentially have a critical role as a therapeutic target in hypertension.
|
30657897 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Our findings define novel molecular mechanism involving interplay between microparticles, the ET-1 system and endothelial cell pro-inflammatory and redox signalling, which may be important in cardiovascular toxicity and hypertension associated with VEGFi anti-cancer treatment.
|
30753341 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
The angiotensin II AT<sub>1</sub> and the endothelin 1 ET<sub>A</sub> receptors play a crucial role in the pathogenesis of cardiovascular diseases like hypertension, heart failure, stroke, pulmonary hypertension, and cardiac hypertrophy.
|
30851407 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 (ET-1) is a potential contributor to sex differences in the pathophysiology of hypertension.
|
30606254 |
2019 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
This resulted in a rapid onset of hypertension, a decrease in eNOS expression, and an increase in endothelin-1 plasma levels, with all mice dying within 5 wk.
|
31196980 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1/nitric oxide balance and HOMA index in children with excess weight and hypertension: a pathophysiological model of hypertension.
|
30923371 |
2019 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Our results indicated that the mechanisms of hypertension in AMA may differ from those in young individuals from the point of VEGF-endothelin-1 system.
|
31272714 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Logistic regression models indicated that hypertension duration (P<0.001, 95% CI: 0.962-0.988) and ET-1 level (P<0.001, 95% CI: 1.144-1.278) were significantly associated with HRP.
|
30651821 |
2019 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In addition, RhoA expression was downregulated when oxidative stress was attenuated by DPI, while Y-27632 decreased the expression of endothelin-1, which is overexpressed in the vascular wall during hypertension.
|
30609027 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 (ET-1), N-terminal fragment of pro-atrial natriuretic peptide (NTpro-ANP), and tumour necrosis factor alpha (TNF-α) in children with primary hypertension and hypertension of renal origin.
|
30359461 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
In summary, in hypertension, pioglitazone shifts the vascular ET<sub>A</sub>/ET<sub>B</sub> ratio, reduces ROS/COX-2 activation and increases NO availability; these changes explain the effect of ET-1 decreasing phenylephrine-induced contraction.
|
31712626 |
2019 |
|
Pulmonary Fibrosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study is the first to demonstrate that PERK activation contributes to pulmonary fibroblast differentiation elicited by ET-1 or thrombin, and the inhibitory activity of CUR against PF is demonstrated herein.
|
30825198 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
CONCLUSIONS In conclusion, plasma D-dimer and ET-1 levels on admission independently predict no-reflow after PCI in STEAMI patients with T2DM.
|
29806659 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Hyperglycemia, hyperinsulinemia, insulin resistance, decrease of glucose transporter, depilation, less activity, flock together, depression, ecchymosis of tongue and tail appearance, the typical diabetic patients "a little more than three" symptoms, as well as the decrease of grip strength, serum cyclic adenosine monophosphate (cAMP)/ cyclic guanosine monophosphate (cGMP) ratio, serum high density lipoprotein-cholesterol (HDL-C) and the increase of serum triglyceride (TG), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), thromboxane B<sub>2</sub> (TXB<sub>2</sub>)/ 6-keto prostaglandin F1α (6-keto PGF1α) ratio, endothelin-1 (ET-1) levels were found in T2DM group.
|
29654829 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serum concentration of big endothelin-1 (ET-1) has prognostic significance in heart failure.
|
29913121 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Concentrations of ET-1 above the median were associated with shorter time to incident HF, MI, cardiovascular mortality, all-cause mortality, and the composite of incident HF/MI/cardiovascular mortality (all log-rank <i>P</i> < 0.001).
|
30213784 |
2018 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The actions of ET-1 are evident during normal adaptive physiological responses and increased under pathophysiological conditions, such as following myocardial infarction and during heart failure, where ET-1 levels are elevated.
|
29470978 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelin-1 (ET-1) and its receptor endothelin A receptor (ET[Formula: see text] have been shown to be upregulated in a high glucose environment, which increase the incidence of diabetes-related heart failure.
|
30149760 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cardiac hypertrophy, induced by neurohumoral factors, including angiotensin II and endothelin-1, is a major predisposing factor for heart failure.
|
29872396 |
2018 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The actions of ET-1 are evident during normal adaptive physiological responses and increased under pathophysiological conditions, such as following myocardial infarction and during heart failure, where ET-1 levels are elevated.
|
29470978 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Concentrations of ET-1 above the median were associated with shorter time to incident HF, MI, cardiovascular mortality, all-cause mortality, and the composite of incident HF/MI/cardiovascular mortality (all log-rank <i>P</i> < 0.001).
|
30213784 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cardiac hypertrophy, induced by neurohumoral factors, including angiotensin II and endothelin-1, is a major predisposing factor for heart failure.
|
29872396 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelin-1 (ET-1) and its receptor endothelin A receptor (ET[Formula: see text] have been shown to be upregulated in a high glucose environment, which increase the incidence of diabetes-related heart failure.
|
30149760 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serum concentration of big endothelin-1 (ET-1) has prognostic significance in heart failure.
|
29913121 |
2018 |